|Articles|September 20, 2021
Seasonal Vaccine Manufacturing v2
Author(s)Baxter BioPharma Solutions
The seasonal influenza vaccine market is projected to reach more than $4 Billion USD by the end of 2022. It is a safe assumption that as demand for seasonal influenza vaccines increases, so too with the demand for contract manufacturing organizations (CMOs) to support.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Developing Next-Gen Cell Lines Using Targeted Integration
2
FAQ: What Precision Analytics Have Done to Advance Next-Gen Biologics
3
FAQ: What You Need to Know about the Current Antibody Pipeline
4
EMA Director Highlights Agency Achievements in 2025
5